Fundraising FoxLeucid
London, GB · 3 known investors
Find your way into Leucid
Sign up to see every warm intro you have to Leucid
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Leucid team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.
Founders & leadership
Investors · 3
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Epidarex Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Related companies · 2
Companies working in the same space as Leucid.
Frequently asked questions
- What does Leucid do?
- Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.
- Who founded Leucid?
- Leucid was founded by John Maher.
- Who are Leucid's investors?
- Leucid's investors include Sofinnova Partners, Vulpes Investment Management, Epidarex Capital.
- Where is Leucid headquartered?
- Leucid is headquartered in London, GB.